TuHURA Biosciences Announces Participation in Upcoming Investor Conferences [Accessibility Statement] Skip NavigationTAMPA, Fla., Feb. 24, 2026 /PRNewswire/ -- TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA" or the "Company"), a Phase 3 immuno-oncology company developing novel therapeutics to overcome resistance to cancer immunotherapy, today announced that Dr. James Bianco, President and Chief Executive Officer, will participate in the following upcoming investor conferences:Citizens Life Science Conferen ...

Iovance Biotherapeutics (NasdaqGM:IOVA) Q4 2025 Earnings call February 24, 2026 08:30 AM ET Speaker9Good day. Thank you for standing by. Welcome to the Iovance Biotherapeutics fourth quarter and full year 2025 financial results and corporate updates conference call. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a question and answer session. To ask a question during this session, you will need to press star one one on your telephone. You will hear ...

First radiotherapeutic agent developed by Radiopharm Ventures, the joint venture between Radiopharm Theranostics and MD Anderson Cancer Center Preclinical animal studies of BetaBart (RV-01) have demonstrated tumor shrinkage and prolonged survival SYDNEY, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Radiopharm Theranostics (ASX:RAD, “Radiopharm” or the “Company”), a clinical-stage biopharmaceutical company focused on developing innovative oncology radiopharmaceuticals for areas of high unmet medical need, today annou ...

Vir Biotechnology (NasdaqGS:VIR) Q4 2025 Earnings call February 23, 2026 05:30 PM ET Company ParticipantsJason O'Byrne - EVP and Interim CFOJohann de Bono - Regius Professor of Cancer ResearchJosh Schimmer - Senior Managing DirectorKiki Patel - Head of Investor RelationsMarianne De Backer - CEO and DirectorMark Eisner - EVP and Chief Medical OfficerPatrick Trucchio - Managing Director of Equity ResearchSean McCutcheon - VP of Biotechnology Equity ResearchConference Call ParticipantsAlec Stranahan - VP and S ...

Core Insights - ImmunityBio's stock surged by 33.1% following the approval of its drug Anktiva in the European Union for treating non-muscle invasive bladder cancer [1][3] Company Developments - Anktiva was previously approved in the U.S. in 2024 and in the U.K. in 2025, with Saudi Arabia granting approval in January of this year [2] - The European Union's regulatory commission has now approved the combination of Anktiva and Bacillus Calmette-Guérin (BCG) for treatment in 30 countries [3] Financial Performance - The company anticipates reporting $113 million in Anktiva revenue for the fiscal year ending in December, with a projected quarter-over-quarter growth of 20% in Q4 2025 [4] Market Potential - ImmunityBio operates in a growing oncology market projected to expand from less than $350 billion last year to over $860 billion by 2034, with the cancer immunotherapy segment expected to reach $277 billion by 2032 [7] - The company has a market capitalization of less than $8 billion, indicating significant growth potential if it captures a portion of the expanding market [7] Drug Pipeline - Anktiva is being tested for additional indications beyond bladder cancer, including solid tumors, Lynch Syndrome, HIV, ovarian cancer, and Non-Hodgkin Lymphoma [6]

Core Viewpoint - OS Therapies Inc. is advancing its regulatory strategy for OST-HER2, a listeria-based cancer immunotherapy, with significant upcoming data releases and regulatory submissions aimed at preventing recurrent pulmonary metastatic osteosarcoma [1][2][3][4]. Regulatory Updates - The company submitted the Non-Clinical and Chemistry, Manufacturing & Controls (CMC) modules of its Biologics License Application (BLA) to the FDA at the end of January 2026 and plans to release additional biomarker data in Q1 2026 [2]. - Conditional Marketing Authorisation Applications (MAAs) are expected to be submitted to the U.K. MHRA and the EMA by the end of Q1 2026, with a Clinical BLA module submission to the FDA anticipated after a Type D meeting in March 2026 [3]. Biomarker Data and Clinical Trials - OS Therapies is conducting follow-on biomarker analyses to further understand the drug's treatment effects and their relationship to clinical outcomes, with data expected to be shared soon [4]. - The company is assembling a meeting with key opinion leaders in osteosarcoma to review clinical and biomarker data and discuss confirmatory trial designs, with plans to initiate a confirmatory trial in Q3 2026 [4][11]. Designations and Financial Implications - OST-HER2 has received Orphan Drug Designation, Fast Track Designation, and Rare Pediatric Disease Designation from the FDA, making it eligible for a Priority Review Voucher (PRV) upon Accelerated Approval, which could be sold for significant value [5]. - The most recent PRV transaction was valued at $200 million [5]. Acquisition and Corporate Developments - OS Therapies acquired listeria-based assets from Ayala Pharmaceuticals in April 2025, and Ayala has since announced its dissolution following the liquidation of its assets [6].

Core Insights - The report highlights the growing momentum in the clinical trial pipeline for iPSC-derived NK cells, with over 12 companies actively developing more than 15 pipeline drugs [1][5] - It provides a comprehensive analysis of the competitive landscape, emerging therapies, and clinical strategies, enabling stakeholders to make informed decisions [1][5] Company and Drug Pipeline Overview - Key companies involved in the development of iPSC-derived NK cells include Centuary Therapeutics, Fate Therapeutics, and Cartherics Pty Ltd, among others [5][6] - Prominent drugs in the pipeline include CNTY-101, FT522, NCR300, and CTH-401, which are at various stages of clinical trials [5][6] Clinical Development and Regulatory Insights - The report includes insights into clinical trial benchmarking, partnering and licensing activities, and regulatory pathways involving the FDA and EMA [1] - Recent developments include Century Therapeutics continuing the CNTY-101 trial and ViGenCell's agreement with Therabest for TB-420, an iPSC-derived NK cell therapy [9] Advantages of iPSC-derived NK Cells - iPSC-derived NK cells offer significant advantages over traditional donor-derived NK cells, including a renewable source, consistent phenotype, and the ability to be genetically engineered for enhanced efficacy [4][5] - Their potential to overcome limitations of primary NK cells positions them as a cornerstone of next-generation immunotherapy [5][6] Market Dynamics and Future Perspectives - The report indicates strong market momentum driven by the unique properties of iPSC-derived NK cells, including clonal uniformity and off-the-shelf manufacturability [5][6] - With advancing clinical validation and regulatory frameworks, iPSC-derived NK cells are expected to become a foundational modality in cancer immunotherapy [5][6]

Core Viewpoint - Immutep Limited has reached 50% of its patient enrollment target in the TACTI-004 Phase III trial for eftilagimod alfa (efti) in combination with KEYTRUDA and chemotherapy for advanced/metastatic non-small cell lung cancer [1][7]. Group 1: Trial Progress and Details - The TACTI-004 trial has enrolled 378 patients globally, with enrollment continuing at a robust pace [3][7]. - The trial is set to complete patient enrollment by the third quarter of 2026, with a futility analysis expected in the first quarter of the same year [2][3]. - The study aims to enroll approximately 756 patients across over 150 clinical sites in more than 25 countries, regardless of PD-L1 expression [4]. Group 2: Efti and Its Mechanism - Efti is a first-in-class MHC Class II agonist that activates antigen-presenting cells to initiate a broad anti-cancer immune response [5]. - The immunotherapy is being evaluated for various solid tumors, including non-small cell lung cancer, and has received Fast Track designation from the FDA for first-line treatments [6]. Group 3: Company Overview - Immutep is a late-stage biotechnology company focused on developing novel immunotherapies for cancer and autoimmune diseases, leveraging its expertise in LAG-3 therapeutics [8].

Core Insights - Moderna, Inc. is a biotechnology company based in Cambridge, Massachusetts, with a market cap of $17.2 billion, known for its messenger RNA medicines and COVID-19 vaccine, and is expanding its pipeline in various therapeutic areas [1] Performance Summary - Over the past 52 weeks, Moderna's shares have increased by 19.3%, outperforming the S&P 500 Index, which rose by 15.5%. Year-to-date, the stock is up 47.9%, while the S&P 500 has only gained 1.9% [2] - Despite this, Moderna has underperformed compared to the iShares Biotechnology ETF, which saw a 26.2% increase over the same period, although it has outperformed the ETF's 3.1% year-to-date return [3] Recent Developments - On January 21, shares surged by 15.8% following positive results from a five-year follow-up study of an experimental skin cancer vaccine in collaboration with Merck, showing a 49% reduction in recurrence or death risk for high-risk melanoma patients [5] Financial Outlook - Analysts project that Moderna's loss per share for the current fiscal year will narrow by 10.9% year-over-year to $7.90. The company has consistently exceeded consensus earnings estimates in the last four quarters [6] - The consensus rating among 24 analysts is a "Hold," with two "Strong Buy," 19 "Hold," one "Moderate Sell," and two "Strong Sell" ratings [6] Analyst Ratings and Price Targets - Edward Tenthoff from Piper Sandler Companies maintains a "Buy" rating with a price target of $63, indicating a potential upside of 44.3%. The current trading price is above the mean price target of $37.40, while the highest price target of $135 suggests a 209.1% premium [8]

Core Insights - CancerVax, Inc. has appointed Dr. George Kemble as Senior Scientific Advisor to enhance its universal cancer treatment platform that utilizes the immune system to combat cancer [1][6]. Company Overview - CancerVax is a pre-clinical biotech company focused on developing a customizable universal cancer treatment platform that aims to detect, mark, and kill only cancer cells [6]. - The company's innovative approach involves disguising cancer cells to resemble well-immunized common diseases, such as measles or chickenpox, to leverage the body's natural immune response [4][6]. Leadership and Expertise - Dr. George Kemble is a seasoned biotech executive with extensive experience in virology, vaccines, and small molecule biologics, previously serving as Chairman of the Board at Sagimet Biosciences Inc. [2]. - His background includes significant roles at MedImmune, where he led research and development efforts, including the launch of FluMist®, the first major innovation in influenza vaccines in over 60 years [3]. Strategic Vision - Dr. Kemble's appointment is expected to bring valuable insights into translating immunology into effective therapies, aligning with CancerVax's mission to reframe cancer as a target the immune system can recognize and defeat [5].